Usmani, S. Z., Mielnik, M., Koh, Y., Alonso Alonso, A., Leleu, X., Quach, H., Min, C., Janowski, W., Abdallah, A., Garg, M., Sandhu, I., Ocio San Miguel, E. M., Oriol, A., Rodriquez-Otero, P., Ramasamy, K., Weisel, K., Besemer, B., Cavo, M., Zhou, X. L., Kaisermann, M. C., Bego Marques, C. M., Williams, D., Carreno, F., Kremer, B. E., Gupta, I. V., & Hus, M. (n.d.). p942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. HemaSphere, 6, 832–833. http://access.bl.uk/ark:/81055/vdc_100159756131.0x000019